XH001 and vaccine-activated T cells for advanced GI cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a two-part treatment: an injection called XH001 plus a custom vaccine that trains your immune cells to attack tumors. It's for people with advanced stomach or bowel cancer that hasn't responded to at least two prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have advanced gastrointestinal cancer that has spread or cannot be removed with surgery, and standard treatments have stopped working or are not an option.
- You have at least one tumor that can be measured on scans, and the largest single tumor is no bigger than 30mm (about an inch).
- Your doctor expects you to live at least 12 more weeks.
- Your blood counts and organ function (kidney, liver) are adequate.
- You have not received a therapeutic cancer vaccine or cell therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
This trial studies a new treatment called XH001 combined with standard immunotherapy and chemotherapy for people whose pancreatic cancer has been surgically removed. The goal is to see if this combination helps prevent the cancer from coming back.
This trial combines a new vaccine (XH001) with chemotherapy after surgery for pancreatic cancer. The vaccine aims to train your immune system to fight any remaining cancer cells, potentially lowering the chance of the cancer coming back.
This trial tests an experimental treatment called GK01, which uses your own immune cells (called tumor-infiltrating lymphocytes) that have been taken from your tumor, multiplied in a lab, and given back to you. It is for people with advanced solid tumors that have not responded to standard treatments, and aims to see if these cells can shrink your cancer.
This study tests an investigational cell therapy (GK01) for people with advanced solid tumors that have grown despite standard treatment or have no standard treatment option. It may help shrink tumors or slow their growth.
This trial tests a combination of three drugs (BC001, Sintilimab, and XELOX chemotherapy) for people with advanced or metastatic HER-2 negative stomach cancer or cancer where the stomach meets the esophagus. The goal is to see if this combination works better than standard treatments.
Hear when a new Gastrointestinal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.